Clinical trials: Clinical Pregnancy
Bladder Cancer, Bladder Stone
A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients.
This study will compare the time required for a cystoscopy procedure in adult participants using the Redpine® Rflex endo(trademark) High-Definition Cystoscope or the site's standard of care reusable flexible cystoscope in…
- Conditions
- Bladder Cancer, Bladder Stone, Bladder Outlet Obstruction, Renal Stone
- Trial name
- NCT06422312
- Testing
- Cystoscopy with RedPine flexible disposable cystoscope, Cystoscopy with standard of care flexible reusable scope
- Where
- 3 sites in United States
- Sponsor
- Guangzhou Red Pine Medical Instrument Co., Ltd.
NMIBC
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus…
- Trial name
- NCT06800963
- Testing
- Intravesical Recombinant Mycobacterium (rMBCG)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Kidney Neoplasms
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.
- Trial name
- S-TRAC (NCT00375674)
- Testing
- Sunitinib malate
- Where
- 115 sites in United States, Australia and 20 more
- Volunteers
- 674 people
- Sponsor
- Pfizer
Overactive Bladder
An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
The goal of this study is to investigate the safety and effectiveness of a new implanted device designed to treat Urinary Urgency-Frequency Syndrome.
- Trial name
- NCT00131573
- Testing
- bion
- Where
- 11 sites in United States
- Volunteers
- 118 people
- Sponsor
- Boston Scientific Corporation
Urinary Tract Infections
Efficacy of BLASTX in Catheter Associated Bacteriuria Versus Standard of Care (SOC)
This is a 2-week, single-site, randomized study in adults requiring short-term (≤ 14 days) catheterization. Subjects will be randomized 1:1 to either the biofilm disrupting gel (BLASTX) or SOC (McKesson Jelly) lubricated…
- Trial name
- NCT03176394
- Testing
- BLASTX Gel, McKesson Jelly
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Next Science TM
Melanoma, Non-small Cell Lung Cancer
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
The goal of this clinical research study is to learn how PLX3397 and pembrolizumab work together to affect cancer cells. PLX3397 is designed to target the receptor for CSF1 (CSF1R).
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST)
- Trial name
- NCT02452424
- Testing
- PLX3397, Pembrolizumab
- Where
- 12 sites in United States
- Volunteers
- 78 people
- Sponsor
- Daiichi Sankyo
Healthy
Beta-hCG Test Reference Range Determination
Prospective, single-centre study to determine the reference range (95th percentile) of human chorionic gonadotropin (hCG) levels in a healthy, non-pregnant, adult female population using the RAMP® Total β-hCG test.
- Trial name
- NCT03485313
- Where
- Canada
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Response Biomedical Corp.
Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4…
- Conditions
- Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms
- Trial name
- NCT04561362
- Testing
- BT8009, Pembrolizumab
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 329 people
- Sponsor
- BicycleTx Limited
Ovarian Cancer, Primary Peritoneal Cancer
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer
The purpose of this study is to determine efficacy of the combination therapy of pemetrexed and carboplatin as treatment for patients with platinum-sensitive ovarian cancer.
- Trial name
- NCT00489359
- Testing
- Pemetrexed - Phase 1, Carboplatin - Phase 1, Pemetrexed - Phase 2
- Where
- 22 sites in Argentina, Canada and 3 more
- Volunteers
- 86 people
- Sponsor
- Eli Lilly and Company
Dysfunctional Uterine Bleeding
CavatermTM vs TCRE in Women With DUB
The purpose of study is to compare the treatment success in the study groups.
- Trial name
- NCT00549159
- Testing
- Thermal Balloon Endometrial Ablation, Transcervical Resection of the Endometrium
- Where
- 2 sites in China
- Volunteers
- 158 people
- Sponsor
- Pnn Medical A/S
Cancer, Solid Tumor
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors.
- Conditions
- Cancer, Solid Tumor, Melanoma, Carcinoma
- Trial name
- NCT05708950
- Testing
- KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kineta Inc.
Atrial Fibrillation
Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction
The objective of the study is to evaluate the effectiveness and safety of the reduced dose rivaroxaban (15 mg once daily) as compared to warfarin in non-valvular atrial fibrillation (NVAF) patients with renal dysfunction in…
- Trial name
- CALLIPER (NCT03359876)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin sodium
- Where
- United States
- Volunteers
- 16,000 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer, Metastatic Cervical Cancer
Safety of Effivia®, a Bevacizumab Biosimilar
This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.
- Conditions
- Metastatic Colorectal Cancer, Metastatic Cervical Cancer, Non Squamous Non Small Cell Lung Cancer
- Trial name
- NCT06313268
- Testing
- Bevacizumab Biosimilar MB02
- Where
- 5 sites in Mexico
- Volunteers
- 83 people
- Sponsor
- Laboratorios Liomont
Renal Artery Stenosis
A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide
Magnetic Resonance Angiography (MRA) is an examination similar to Magnetic Resonance Imaging (MRI) which uses a magnetic field and a contrast medium when needed to visualize blood flow in the arterial vessels throughout the body.
- Trial name
- NCT00209391
- Testing
- Gadodiamide Injection
- Where
- Germany
- Volunteers
- 395 people
- Sponsor
- GE Healthcare
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
ccRCC, Clear Cell Renal Cell Carcinoma
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
- Conditions
- ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms
- Trial name
- NCT05119335
- Testing
- Oral NKT2152
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- NiKang Therapeutics, Inc.
Urinary Bladder, Neurogenic
Connected Catheter Clinical Feasibility Study( CFS)
The objective of this study is to evaluate the safety and essential performance of the Connected Catheter System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting, and during and…
- Trial name
- NCT03405285
- Testing
- Connected Catheter
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Spinal Singularity
Overactive Bladder
Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder
The purpose of this study is to evaluate the change from baseline between the active and sham treatment groups in the treatment of urgency (urinary) incontinence episodes (leaks).
- Trial name
- Beacon (NCT01369485)
- Testing
- (VERV™ System)
- Where
- 14 sites in United States
- Volunteers
- 163 people
- Sponsor
- Ethicon Endo-Surgery
Pregnancy Rate, Oocytes
A Study to Evaluate the Effect of Ovaleap® on the Pregnancy Rate and Clinical Effects as Well as the User-friendliness of the Ovaleap®-Pen.
The aim of this non-interventional study is to extend the knowledge on effectiveness of Ovaleap® (number of oocytes and pregnancy rate) during routine IVF- or ICSI-treatment using a Gonadotropin-releasing hormone (GnRH)…
- Trial name
- NCT02809989
- Testing
- Ovaleap®
- Where
- 37 sites in Germany
- Volunteers
- 507 people
- Sponsor
- Teva Pharma GmbH
Carcinoma, Renal Cell
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be: At least 18 years of age or older.
- Trial name
- NCT05534789
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Pfizer